Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Novel RAF Inhibitor Active Across Multiple Tumor Types

April 4th 2017

Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with BRAF V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.

Dr. Papa on Challenges of CAR T-Cell Therapy in Head and Neck Cancer

April 1st 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Dr. Koyfman on Reirradiation Options for Head and Neck Cancer

March 31st 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses reirradiation options for patients with head and neck cancer.

Dr. Yarmand Discusses Targeting ATF4 in Thyroid Cancer

March 29th 2017

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses targeting ATF4 in medullary thyroid cancer.

Dr. Lorch on the Treatment of Medullary Thyroid Cancer

March 29th 2017

Jochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.

Nivolumab Recommended for EU Approval in Head and Neck Cancer

March 24th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.

Seiwert Summarizes Immunotherapy Advances in Head and Neck Cancer

March 24th 2017

Tanguy Seiwert, MD, discussed advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.

Dr. Seiwert on Advice With Immunotherapy for Head and Neck Cancer

March 23rd 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, gives advice to community oncologists on administering immunotherapy to patients with head and neck cancer.

Dr. Koyfman on Informing Patients of Reirradiation for Head and Neck Cancer

March 23rd 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

Dr. Vokes on Biomarker Selection in Head and Neck Cancer

March 22nd 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

March 19th 2017

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Dr. Koyfman on IMRT and SBRT Reirradiation for Head and Neck Cancer

March 16th 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reirradiation for patients with head and neck cancer.

Dr. Koyfman on Advancements in Technology and Safety of Treatments in Head and Neck Cancer

March 9th 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses advancements in technology and safety of treatments for patients with head and neck cancer.

Dr. Bastholt on Lenvatinib in Thyroid Cancer

March 7th 2017

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.

Dr. Nikiforov on Reclassifying Subtype of Thyroid Cancer

March 3rd 2017

Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Expert Discusses Optimizing Adjuvant CRT in Head and Neck Cancer

February 28th 2017

Samuel Swisher-McClure, MD, discusses the results of a recent retrospective, observational cohort study that examined use and survival outcomes of adjuvant chemoradiotherapy in patients with resected locally advanced head and neck cancer.

Researchers Identify Criteria for Refining Adjuvant CRT Use in Head and Neck Cancer

February 27th 2017

The number of positive lymph nodes is an appropriate selection factor in deciding adjuvant chemoradiotherapy use in some patients with locally advanced head and neck cancer.

Specialty Pharmacy: Build, Buy, or Partner

February 22nd 2017

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Dr. Seiwert on Ongoing Trials in Head and Neck Cancer

February 20th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.

Dr. Vokes on Different Settings in Head and Neck Cancer

February 16th 2017

Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.